An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program

Author:

Tran Quyen1,Warren Joan L2,Barrett Michael J3,Annett Dave3,Marth Melissa4,Cress Rosemary D5,Deapen Dennis6,Glaser Sally L7,Gomez Scarlett L7,Schwartz Stephen M8,Li Christopher I8,Wu Xiao-Cheng9,Enewold Lindsey2,Harlan Linda C2,Rivera Donna R2,Winn Deborah M2,Penberthy Lynne2,Cronin Kathleen A2

Affiliation:

1. Food and Drug Administration, Silver Spring, MD

2. National Cancer Institute, Bethesda, MD

3. Information Mangement Services, Inc., Calverton, MD

4. IQVIA, Rockledge, PA

5. Cancer Registry of Greater California, Sacramento, CA

6. University of Southern California, Los Angeles, CA

7. University of California San Francisco, Fremont, CA

8. Fred Hutchinson Cancer Research Center, Seattle, WA

9. Louisiana State University Health Sciences Center, New Orleans, LA

Abstract

Abstract Oral anticancer medications (OAMs) are increasingly utilized. We evaluated the representativeness and completeness of IQVIA, a large aggregator of pharmacy data, for breast cancer, colon cancer, chronic myeloid leukemia, and myeloma cases diagnosed in six Surveillance, Epidemiology, and End Results Program (SEER) registries between 2007 and 2011. Patient’s SEER and SEER-Medicare data were linked and compared with IQVIA pharmacy data from 2006 to 2012 for specific OAMs. Overall, 67.6% of SEER cases had a pharmacy claim in IQVIA during the treatment assessment window. This varied by location, race and ethnicity, and insurance status. IQVIA consistently identified fewer cases who received an OAM of interest than SEER-Medicare. The difference was least pronounced for breast cancer agents and most pronounced for myeloma agents. The IQVIA pharmacy database included a large portion of persons in the SEER areas. Future studies should assess receipt of OAMs for other cancer sites and in different SEER registries.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology,General Medicine

Reference18 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3